D'Avila Ângela Marcon, Capp Edison, Corleta Helena von Eye
Graduate Program in Medicine: Medical Sciences, Faculdade de Medicina da Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Rev Bras Ginecol Obstet. 2017 Apr;39(4):162-168. doi: 10.1055/s-0037-1601438. Epub 2017 Apr 11.
To assess ovarian reserve (OVR) by means of follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH), and antral follicle count (AFC) measurement in eumenorrheic women with breast cancer, exposed to gonadotoxic chemotherapy. Fifty-two women (35.3 ± 3.8 years old) with breast cancer and undergoing cyclophosphamide-containing chemotherapy were enrolled. The assessment was performed before chemotherapy (T1) and after 2 (T2) and 6 months (T3). Six months after chemotherapy, the prevalence of regular cycles was 60%. Anti-Müllerian hormone decreased down to undetectable levels at T2 and T3 (T1: 2.53 [1.00-5.31]; T2 < 0.08; T3: < 0.08 [< 0.08-1.07] ng/mL), ( < 0.0001). Antral follicle count was 11 [8.0-13.5] follicles at T1 and lower at T2 (5.50 [3.75-8.0] and T3 (5.0 [2.5-7.0]) ( < 0.0001). In patients who remained with regular cycles during chemotherapy or resumed normal menses, FSH and estradiol levels remained unchanged. Anti-Müllerian hormone and AFC are useful as markers of OVR decline in women exposed to chemotherapy. Follicle-stimulating hormone is only adequate in women who become amenorrheic.
通过测量促卵泡激素（FSH）、抗苗勒管激素（AMH）和窦卵泡计数（AFC）来评估接受性腺毒性化疗的月经正常的乳腺癌女性的卵巢储备（OVR）。招募了52名患有乳腺癌且正在接受含环磷酰胺化疗的女性（年龄35.3±3.8岁）。在化疗前（T1）、化疗后2个月（T2）和6个月（T3）进行评估。化疗6个月后，月经周期规律的患病率为60%。抗苗勒管激素在T2和T3时降至检测不到的水平（T1：2.53[1.00 - 5.31]；T2＜0.08；T3：＜0.08[＜0.08 - 1.07]ng/mL），（P＜0.0001）。窦卵泡计数在T1时为11[8.0 - 13.5]个卵泡，在T2时较低（5.50[3.75 - 8.0]），在T3时为5.0[2.5 - 7.0]）（P＜0.0001）。在化疗期间月经周期保持规律或恢复正常月经的患者中，FSH和雌二醇水平保持不变。抗苗勒管激素和AFC可作为接受化疗女性OVR下降的标志物。促卵泡激素仅适用于闭经的女性。
